Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Y-90 SIRT in Advanced Intrahepatic Biliary Tract Cancer
NCT04238637Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2019
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Started Nov 2019; status: active, not recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04238637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238637.